Every material Form 8-K Travere Therapeutics, Inc. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Travere Therapeutics reported third quarter 2026 U.S. net product sales of $220.2 million, up from $113.2 million a year earlier, with FILSPARI accounting for $200.2 million. The company swung to a GAAP net loss of $52.3 million, or $0.55 per basic share, from net income of $25.7 million a year earlier, mainly because of a $113.1 million IPR&D expense tied to its Everest Medicines licensing agreement for civorebrutinib.
U.S. net product sales were $220.2 million in Q3 2026 versus $113.2 million in Q3 2025; FILSPARI sales were $200.2 million, up 120% year over year.
GAAP net loss was $52.3 million, or $0.55 per basic share, compared with net income of $25.7 million, or $0.29 per share, in Q3 2025.
Non-GAAP adjusted net loss was $29.6 million, or $0.31 per basic share, for Q3 2026.
Cash, cash equivalents and marketable securities were $471.8 million as of September 30, 2026. CEO Eric Dube will hand over to Bradley Campbell effective December 1, 2026.
Travere Therapeutics said CEO Eric Dube will step down as President, CEO and board member effective December 1, 2026, and Bradley L. Campbell, former CEO of Amicus Therapeutics, will succeed him in both roles on the same date. Dube will stay on as Executive Advisor through February 15, 2027, and his employment ends February 16, 2027, unless the two sides agree to an earlier date. The change is a planned leadership transition under agreements both parties signed on September 21, 2026.
Eric Dube's CEO and board roles end December 1, 2026; Bradley L. Campbell takes both roles that day.
Dube's employment is scheduled to end February 16, 2027, and he will serve as a consultant for up to 18 months after the resignation date.
Campbell's employment agreement sets a $1,000,000 base salary, a target bonus of 85% of base salary, and approximate equity grants of $8,250,000 in stock options and $8,250,000 in restricted stock units.
Dube will not be eligible for the 2027 cash bonus program and will receive no further stock awards, though existing awards keep vesting.
Travere reported second quarter 2026 U.S. net product sales of $161.4 million, up from $94.8 million a year earlier, with FILSPARI sales growing 96% to $141.1 million. The GAAP net loss widened to $34.8 million, or $0.37 per basic share, mainly due to a $40.0 million inducement expense from 2029 convertible note repurchases, so strong sales growth is offset by a larger reported loss for shareholders.
U.S. net product sales were $161.4 million in Q2 2026 versus $94.8 million in Q2 2025; FILSPARI accounted for $141.1 million.
GAAP net loss was $34.8 million, or $0.37 per basic share, versus $12.8 million, or $0.14 per share, a year earlier.
A $40.0 million inducement expense tied to 2029 convertible note repurchases in Q2 2026 drove much of the increase in other expense.
In July 2026 the company closed the civorebrutinib in-licensing deal with Everest Medicines and made a $112.5 million upfront payment.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Travere Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →